Bayer reports phase I results for prostate cancer therapy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Bayer Reports Results for the Investigational Targeted Radionuclide Therapy ²²⁵Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer
February 27, 2026 12:43 PM ESTÂ 225Ac-PSMA-Trillium (BAY 3563254) is an investigational targeted alpha therapy (TAT) being developed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC) Data from PAnTHa, the global Phase I first-in-human, dose-escalation study were presented during the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, CA Data support advancing 225Ac-PSMA-Trillium to the next phase of development Prostate cancer is the second most common diagnosed cancer in men1, with less than three years median survival among metastatic patients, who have developed castration-resistance2 TAT is a strategic pillar of precision oncology at... More
